\
&
Contact us
\
&
Contact us
Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsPublished on • 1 year ago
These testimonials share at least one programme or target audience.
The European Holocaust Research Infrastructure Implementation Phase (EHRI-IP) project was funded under Horizon Europe call topic HORIZON-INFRA-2023-DEV-01-02. The project duration was two years and came to an end in February 2026. The main objective of the EHRI-IP project was to undertake all necessary legal, financial and strategic work to have a permanent organisation or ERIC (European Research Infrastructure Consortium) fully operational by the end of the implementation phase. The project consortium consisted of 14 partners from 13 countries. Read more about the project and the contribution of Flemish partner Kazerne Dossin in this testimonial.
